Providence Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
64
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$7.73M
- Investors
-
4
Providence Therapeutics General Information
Description
Operator of a biotechnology company intended to create messenger RNA (mRNA) vaccine therapies. The company focuses on oncology research, personalized cancer therapies, drug product development, and vaccine manufacturing, enabling clinics to have access to safe and effective vaccines.
Contact Information
Website
www.providencetherapeutics.comCorporate Office
- 120 - 8832 Blackfoot Trail South East
- Calgary, Alberta T2J 3J1
- Canada
Corporate Office
- 120 - 8832 Blackfoot Trail South East
- Calgary, Alberta T2J 3J1
- Canada
Providence Therapeutics Timeline
Providence Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 01-Sep-2022 | $7.73M | Completed | Clinical Trials - Phase 2 | ||
| 6. Grant | 23-Jul-2021 | Completed | Clinical Trials - Phase 2 | |||
| 5. Grant | 27-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 07-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 3. Later Stage VC | 23-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Feb-2018 | $1.4M | Completed | Pre-Clinical Trials | ||
| 1. Seed Round | 03-Aug-2016 | $1.4M | $1.4M | Completed | Pre-Clinical Trials |
Providence Therapeutics Comparisons
Industry
Financing
Details
Providence Therapeutics Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CureVac | Formerly VC-backed | Tubingen, Germany | ||||
| Gritstone bio | Formerly VC-backed | Emeryville, CA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| Nutcracker Therapeutics | Venture Capital-Backed | Emeryville, CA | ||||
| ReCode Therapeutics | Venture Capital-Backed | Menlo Park, CA |
Providence Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Providence Therapeutics Patents
Providence Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3154578-A1 | Compositions and methods for the prevention and/or treatment of covid-19 | Pending | 08-Apr-2022 | ||
| CA-3146411-A1 | Compositions and methods for prevention and/or treatment of covid-19 | Pending | 21-Jan-2022 | ||
| CA-3143650-A1 | Lipids and compositions thereof | Pending | 22-Dec-2021 | ||
| AU-2022419419-A1 | Ionizable disulfide lipids and lipid nanoparticles derived therefrom | Pending | 22-Dec-2021 | ||
| CA-3241972-A1 | Ionizable disulfide lipids and lipid nanoparticles derived therefrom | Pending | 22-Dec-2021 | A61K9/5123 |
Providence Therapeutics Executive Team (9)
| Name | Title | Board Seat |
|---|---|---|
| Bradley Sorenson | Co-Founder, President, Chief Executive Officer & Board Member | |
| Natalia Orozco | Chief Scientific Officer | |
| Eric Marcusson Ph.D | Co-Founder & Board Member | |
| Scott Leary MD | Co-Founder & Board Member | |
| Aleksandra Pastrak Ph.D | Chief Medical Officer |
Providence Therapeutics Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bradley Sorenson | Providence Therapeutics | Co-Founder, President, Chief Executive Officer & Board Member | |
| Donna Ward JD | Self | Board Member | |
| Eric Marcusson Ph.D | Providence Therapeutics | Co-Founder & Board Member | |
| Ken Hughes | Self | Chairman | |
| Scott Leary MD | Providence Therapeutics | Co-Founder & Board Member |
Providence Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Providence Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bill & Melinda Gates Foundation | Not-For-Profit Venture Capital | |||
| NRC-IRAP | Government | Minority | ||
| IRAP | Government | Minority | ||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator |
Providence Therapeutics FAQs
-
When was Providence Therapeutics founded?
Providence Therapeutics was founded in 2015.
-
Who is the founder of Providence Therapeutics?
Bradley Sorenson, Eric Marcusson Ph.D, and Scott Leary MD are the founders of Providence Therapeutics.
-
Who is the CEO of Providence Therapeutics?
Bradley Sorenson is the CEO of Providence Therapeutics.
-
Where is Providence Therapeutics headquartered?
Providence Therapeutics is headquartered in Calgary, Canada.
-
What is the size of Providence Therapeutics?
Providence Therapeutics has 64 total employees.
-
What industry is Providence Therapeutics in?
Providence Therapeutics’s primary industry is Drug Discovery.
-
Is Providence Therapeutics a private or public company?
Providence Therapeutics is a Private company.
-
What is Providence Therapeutics’s current revenue?
The current revenue for Providence Therapeutics is .
-
How much funding has Providence Therapeutics raised over time?
Providence Therapeutics has raised $8.1M.
-
Who are Providence Therapeutics’s investors?
Bill & Melinda Gates Foundation, NRC-IRAP, IRAP, and Johnson & Johnson Innovation - JLABS have invested in Providence Therapeutics.
-
Who are Providence Therapeutics’s competitors?
CureVac, Gritstone bio, BioNTech, Nutcracker Therapeutics, and ReCode Therapeutics are some of the 6 competitors of Providence Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
